Gå direkt till innehåll
Vipera berus
Vipera berus

Pressmeddelande -

Scandinavian Biopharma enters into an exclusive agreement with Flynn Pharma for ViperaTAb

Scandinavian Biopharma today announces that the company has entered into an exclusive agreement with Flynn Pharma for the viper antivenom ViperaTAb.

Under the new agreement, Scandinavian Biopharma will have exclusive rights to service and make ViperaTAb available for emergency use in the Nordics, Baltic States and Germany.

“We are very pleased to strengthen our portfolio with an important antivenom for Northern Europe” says Björn Sjöstrand, CEO at Scandinavian Biopharma. “

ViperaTAb is not registered in the European Union but is available under special permission. 

For more information, please contact:
Björn Sjöstrand, CEO: +46 727-125 120, bjorn.sjostrand@scandinavianbiopharma.se

Ämnen


Scandinavian Biopharma

Scandinavian Biopharma is a Swedish research-based biotech company specialist in marketing and sales of vaccines, immunoglobulin's, biodefense, antidotes and diagnostic tests.

Research and development is mainly focused on development of a new oral traveler’s diarrhea vaccine in collaboration with PATH Vaccine Solutions and University of Gothenburg.

www.scandinavianbiopharma.se

Kontakter

Relaterat innehåll